Van Strum & Towne Inc. Acquires 326 Shares of Edwards Lifesciences Co. (NYSE:EW)

Van Strum & Towne Inc. grew its holdings in Edwards Lifesciences Co. (NYSE:EW) by 4.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,134 shares of the medical research company’s stock after purchasing an additional 326 shares during the period. Van Strum & Towne Inc.’s holdings in Edwards Lifesciences were worth $528,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Wellington Management Group LLP increased its holdings in shares of Edwards Lifesciences by 86.3% in the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after purchasing an additional 14,610,123 shares in the last quarter. State Street Corp boosted its stake in shares of Edwards Lifesciences by 1.0% in the 3rd quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock worth $1,733,270,000 after buying an additional 256,538 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Edwards Lifesciences by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company’s stock worth $889,050,000 after buying an additional 284,918 shares during the last quarter. Fisher Asset Management LLC boosted its stake in shares of Edwards Lifesciences by 7.7% in the 4th quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company’s stock worth $723,664,000 after buying an additional 696,965 shares during the last quarter. Finally, Jennison Associates LLC purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth $555,939,000. Institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Wolfe Research downgraded Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. Citigroup raised their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Truist Financial reiterated a “hold” rating and set a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and lifted their target price for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. Finally, Evercore ISI lowered their target price on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $79.95.

Insiders Place Their Bets

In other Edwards Lifesciences news, CEO Bernard J. Zovighian sold 6,164 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.51, for a total transaction of $428,459.64. Following the sale, the chief executive officer now directly owns 59,083 shares of the company’s stock, valued at $4,106,859.33. The trade was a 9.45 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 400 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.48, for a total value of $27,792.00. Following the sale, the vice president now directly owns 22,588 shares in the company, valued at $1,569,414.24. The trade was a 1.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 53,803 shares of company stock valued at $3,900,976 over the last ninety days. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Trading Up 2.1 %

Shares of EW stock opened at $69.37 on Friday. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock’s 50-day moving average price is $71.74 and its 200-day moving average price is $70.32. The stock has a market capitalization of $40.78 billion, a price-to-earnings ratio of 9.95, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Equities research analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.